GSK
GSK
931 hedge funds and large institutions have $14.4B invested in GSK in 2022 Q1 according to their latest regulatory filings, with 104 funds opening new positions, 351 increasing their positions, 275 reducing their positions, and 79 closing their positions.
66% more call options, than puts
Call options by funds: $342M | Put options by funds: $206M
32% more first-time investments, than exits
New positions opened: 104 | Existing positions closed: 79
28% more repeat investments, than reductions
Existing positions increased: 351 | Existing positions reduced: 275
18% more capital inflows, than outflows
Capital inflows: $1.05B | Capital outflows: $891M
1% more funds holding
Funds holding: 920 → 931 (+11)
0% less ownership
Funds ownership: 13.03% → 13.03% (-0%)
11% less funds holding in top 10
Funds holding in top 10: 19 → 17 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JTC Employer Solutions Trustee
St Helier,
Jersey
|
+$131M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$103M |
| 3 |
Goldman Sachs
New York
|
+$101M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$96.8M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$70M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
-$120M |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
-$106M |
| 3 |
Two Sigma Investments
New York
|
-$83.2M |
| 4 |
Camber Capital Management
Boston,
Massachusetts
|
-$65.2M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$57.3M |
GSK Hedge Fund Activity: Q1 2022 in Review
931 of the 6,364 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2022, worth a combined $14.4B — down 0.13% from $14.5B a quarter earlier.
Buyers outnumbered sellers: 104 funds opened new GSK positions and 79 closed out — a net gain of 25 holders — while 351 added to existing stakes and 275 trimmed.
The largest buyer was JTC Employer Solutions Trustee, adding an estimated $131M. The largest seller was Dodge & Cox, cutting an estimated $120M.
- 931 institutional investors held GSK (GSK) as of Q1 2022, up from 920 in Q4 2021.
- Funds reported $14.4B of GSK stock for Q1 2022, down 0.13% quarter-over-quarter.
- 104 funds opened new GSK positions in Q1 2022 and 79 closed out, a net change of +25 holders.
- The largest GSK buyer in Q1 2022 was JTC Employer Solutions Trustee, an estimated $131M added.
- The largest GSK seller in Q1 2022 was Dodge & Cox, an estimated $120M sold.
Based on aggregated 13F filings for Q1 2022.